Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anavex Life Sciences Corp. - Common Stock (NQ:AVXL)

2.620 -0.040 (-1.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Anavex Life Sciences Crashes As Last-Minute Testing Edits Cloud Drug's Impact ↗
Just two weeks ago, Anavex edited the goals of its study in Rett syndrome. 
Via Investor's Business Daily
News headline image
34 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K... 
Via Benzinga
News headline image
Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals ↗
Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome. 
Via Benzinga
News headline image
Mid-Day Market Update: Pitney Bowes Drops After Q4 Earnings; Biofrontera Shares Climb ↗
US stocks traded mostly flat on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses. 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views ↗
US stocks started the first trading day of new month on a cautious note after recording gains on Monday. Wall Street closed the volatile January month with steep losses. 
Via Benzinga
News headline image
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $31.66 during Friday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
News headline image
Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study ↗
Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus ↗
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year ↗
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers iSpecimen (NASDAQ:ISPC) shares in... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
News headline image
Earnings Scheduled For November 24, 2021 ↗
Companies Reporting Before The Bell • Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million. • Anavex Life... 
Via Benzinga
News headline image
Earnings Outlook For Anavex Life Sciences ↗
Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1... 
Via Benzinga
News headline image
Why Is Biogen Pursuing a New Direction in Alzheimer's Research? ↗
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
News headline image
Anavex Life Sciences (AVXL) Q3 2021 Earnings Call Transcript ↗
AVXL earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For August 12, 2021 ↗
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
News headline image
70 Biggest Movers From Yesterday ↗
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private... 
Via Benzinga
News headline image
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday ↗
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers NanoVibronix (NASDAQ:NAOV) share... 
Via Benzinga
News headline image
Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study ↗
Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Cocrystal Pharma (NASDAQ:COCP) stock moved upwards by 30.9% to $1.44 during Thursday's pre-market session. The company's market cap stands at $140.3... 
Via Benzinga
News headline image
21 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Creatd Inc (NASDAQ: CRTD) shares rose 33.9% to $4.27 in pre-market trading after dropping around 9% on Friday. Oxbridge Re Holdings Ltd (NASDAQ: OXBR) shares rose 13.2%... 
Via Benzinga
News headline image
Biogen Stock Drags On Alzheimer's Players As FDA Requests Review Of Aduhelm Approval ↗
Biogen stock tumbled Friday after the FDA requested an independent review of the process that led to its recent Alzheimer's approval. 
Via Investor's Business Daily
News headline image
Cramer Shares His Thoughts On Anavex Life Sciences, Upstart And More ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is intrigued about Anavex Life Sciences Corp (NASDAQ: AVXL) because Biogen Inc (NASDAQ: BIIB) data doesn... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.